Take2 Health provides Take2 Prophecy™, a non‑invasive blood test that screens for early‑stage nasopharyngeal carcinoma by analyzing plasma DNA for Epstein–Barr virus and NPC‑specific genetic markers using next‑generation sequencing. 7% false‑positive rate within 3–7 working days, reviewed by physicians for follow‑up care.
Funding
Funding not disclosed
Founders
Product
Problem
Nasopharyngeal carcinoma (NPC) often presents with vague or no symptoms, leading to late diagnosis; in Hong Kong the 5‑year survival drops below 70% when detected at an advanced stage.
Solution
Take2 Health offers Take2 Prophecy™, a non‑invasive blood‑based screening test that detects early‑stage NPC by analysing plasma DNA for Epstein–Barr virus and NPC‑specific genetic signatures using next‑generation sequencing (NGS). The assay achieves >97 % sensitivity and a false‑positive rate of 0.7 %, delivering clinically validated results within 3–7 working days. Results are reviewed by physicians who explain the findings and advise follow‑up care. The service can be incorporated into routine health checks or offered as a standalone test for asymptomatic individuals and those with suspected symptoms.
Target Audience
Primary customers are adults in Hong Kong—both asymptomatic individuals and those with mild, non‑specific symptoms—who seek early cancer detection through routine health examinations or dedicated NPC screening.
Features
- Blood draw only; no imaging or invasive procedures required
- NGS‑based detection of plasma EBV DNA and NPC‑associated genetic markers
- Clinically validated performance: >97 % sensitivity, 0.7 % false‑positive rate
- Turnaround time of 3–7 working days with results reviewed by qualified physicians
- Integrated into comprehensive cancer‑screening packages covering common local cancers
- Available at multiple accredited service locations across Hong Kong